Combination Therapy Shows Good Results For Acute Myeloid Leukemia

Venetoclax plus cobimetinib or idasanutlin may be synergistic and down-regulate a protein that develops disease resistance.

Venetoclax in combination with cobimetinib or idasanutlin for relapsed or refractory acute myeloid leukemia (AML) has a complete response in up to 50 percent patients.

The clinical trial followed patients who received therapy for a prior blood disease and who were not eligible for cytotoxic therapy.

Acute Lymphoblastic Leukemia - Incidence Causes Symptoms Diagnosis Treatment Prognosis
Acute lymphoblastic leukemia (ALL) is the cancer of white blood cells characterized by excess lymphoblasts. It is the most common of all childhood cancers and can be fatal in weeks if left untreated.

‘Venetoclax in combination with cobimetinib or idasanutlin for a prior blood disease, refractory acute myeloid leukemia, had minimal side effects.’

Preliminary results from the ongoing dose-escalation study, demonstrate that the combination therapies can be safely administered with minimal side effects.

"This is the first clinical study evaluating new oral combinations with venetoclax in AML patients," said Konopleva. "This is significant as effective treatment options for patients with relapsed and/or refractory AML are limited."

Venetoclax, which inhibits the B-cell lymphoma protein (BCL-2) that makes cancer cells resistant to therapy, was previously FDA-approved for treatment of chronic lymphocytic leukemia (CLL).

Blood Cancer Treatment Outcome Depends on Genetic Make Up of Proteins
The genetic make-up can impact the activity of the immune system and the body's ability to fight cancer.

Idasanutlin is an investigational drug targeting a protein called MDM2 which impacts the tumor suppressor gene p53, while cobimetinib targets a protein known as MEK within the cancer cell and is FDA-approved for treatment of advanced melanoma with BRAF mutation.

Andreeff and Konopleva also led the pre-clinical investigation resulting in the clinical trial. The pre-clinical research demonstrated unprecedented in vivo activity, as well as a new molecular mechanism explaining how the inhibitor drugs impact MDM2 which is tied to regulation of p53, and BCL2 - both linked to cell death.

Combination Drug Therapy - A new strategy For Brain and Blood Cancers
Brain and Blood cancers can be treated by using drug combination as a new strategy, reveals study.

Pre-clinical data also showed that venetoclax plus cobimetinib or idasanutlin may be synergistic. MEK and MDM2 inhibition have been shown to down-regulate a protein in the BCL-2 family, MCL-1, overcoming the major resistance mechanism to BCL-2 inhibition in AML.

"We demonstrated that p53 activation overcomes the resistance to BCL-2 inhibition by promoting MCl-1 degradation and overcoming cell death response by altering cellular response," said Andreeff.

Tumor Suppressor Protein Promotes Deadly Form of Blood Cancer
The interaction between FLT3 mutations and RUNX1 activity in the induction of acute myeloid leukemia, was explored in the study.

"These findings laid the foundation for the development of the current combination clinical trial for AML, bringing together different investigations in my group that extended over 15 years."

Dose escalation is being used in the clinical trial to establish the maximum tolerated dose for each drug combination in the elderly patient with relapsed AML, an area of unmet need, according to Daver.

"The best response rates, up to 50 percent in relapsed AML, were seen for the combination of venetoclax and idasanutlin, in line with the preclinical data," he said. "However, these results will require confirmation in larger patient groups."

Source-Eurekalert